clinical trial · NCT04381832
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Prostatic Neoplasms, Castration-ResistantAndrogen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic NeoplasmsProstatic Cancer, Castration-ResistantEtrumadenantZimberelimabQuemliclustatEnzalutamideDocetaxelSG
brief summary
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
started
Jul 7, 2020
primary completion
Aug 30, 2024
completion
Aug 30, 2024
last updated
Jul 22, 2025
official title
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol